首页> 美国卫生研究院文献>Current Therapeutic Research Clinical and Experimental >Status of lipid-lowering therapy prescribedbased on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP)
【2h】

Status of lipid-lowering therapy prescribedbased on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP)

机译:根据2002年日本动脉粥样硬化学会诊断和治疗成人高脂血症指南中的建议所规定的降低脂质疗法的现状:日本脂质评估计划(J-LAP)的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background:In its 1997 Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults and subsequent revisions, the Japan10 Atherosclerosis Society (JAS) recommends serum lipid management goals (SLMGs) based on a coronary heart disease (CHD) risk classification. A literature search revealed that the status of lipid-lowering therapy based on the current JAS recommendations in Japan has not been assessed.
机译:背景:Japan10动脉粥样硬化学会(JAS)在其1997年《日本成年人高脂血症的诊断和治疗指南》及后续修订中,建议根据冠心病(CHD)风险分类制定血清脂质管理目标(SLMG)。文献检索表明,目前尚未评估基于日本JAS现行建议的降脂治疗现状。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号